Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

828
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
828
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.5K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.8K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

159
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
159

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum: Enhancing Data Quality and Remote Accessibility in Clinical Trials: A SeroSelectTB Case Study in Ethiopia, Tanzania, and South Africa.

Applied clinical informatics·2026
Same author

Enhancing Data Quality and Remote Accessibility in Clinical Trials: A SeroSelectTB Case Study in Ethiopia, Tanzania, and South Africa.

Applied clinical informatics·2026
Same author

Lineage-Specific Proteomic Signatures in the <i>Mycobacterium tuberculosis</i> Complex Reveal Differential Abundance of Proteins Involved in Virulence, DNA Repair, CRISPR-Cas, Bioenergetics and Lipid Metabolism.

Frontiers in microbiology·2020
Same author

Rift valley fever: diagnostic challenges and investment needs for vaccine development.

BMJ global health·2020
Same author

Diagnostic applications for Lassa fever in limited-resource settings.

BMJ global health·2019
Same author

Vitamin D Deficiency is Associated with Increased Use of Antimicrobials among Preschool Girls in Ethiopia.

Nutrients·2019

Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.0K

Tuberculosis management time: an alternative parameter for measuring the tuberculosis infectious pool.

Solomon A Yimer1,2,3,4, Carol Holm-Hansen1, Dag G Storla5

  • 1Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.

Tropical Medicine & International Health : TM & IH
|January 8, 2014
PubMed
Summary

Tuberculosis (TB) management time effectively estimates the infectious pool, aiding in monitoring TB control programs. This method quantizes infectious person-days, offering a new metric for public health interventions.

Keywords:
EthiopiaTB management timeTuberculosiscase detection ratediagnostic delaytreatment delay

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

17.1K

Related Experiment Videos

Last Updated: May 4, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.0K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

17.1K

Area of Science:

  • Public Health
  • Epidemiology
  • Infectious Disease Control

Background:

  • Tuberculosis remains a significant global health challenge, necessitating accurate methods for estimating infectiousness.
  • Understanding the infectious pool is crucial for effective tuberculosis control strategies.

Purpose of the Study:

  • To evaluate tuberculosis (TB) management time as a novel parameter for estimating the infectious pool.
  • To assess TB management time in West Gojjam Zone, Amhara Region, Ethiopia.

Main Methods:

  • The study defined TB management time as the duration from cough onset to TB treatment initiation.
  • Infectious period was determined using TB management time, including sputum smear-positive, smear-negative, retreatment, and estimated undetected TB cases.
  • The infectious pool was quantified as annual infectious person-days per population.

Main Results:

  • Undiagnosed TB cases and sputum smear-positive patients significantly contributed to the infectious pool.
  • The total estimated infectious pool was 325,410 person-days annually, or 15,447 person-days per 100,000 population.

Conclusions:

  • Tuberculosis management time serves as a viable alternative parameter for estimating the community's infectious TB pool.
  • Recording TB management time can enhance the monitoring of TB control program performance.